NurExone Reports Preclinical Results of ExoPTEN for the Treatment of Traumatic Spinal Cord Injuries
Shots:
- The company highlights results from the preclinical study evaluating the impact of ExoPTEN on the motor, reflex, and sensory recovery of rats following the complete serving of the spinal cord
- The results depicted that 75% of the rats in the ExoPTEN-treated group responded to treatment and recovered hind limb reflex, rehabilitated some motor function & recovered sensory control. In the exosome-only & PTEN siRNA molecule treated group, 25% of rats responded to treatment and recovered hind limb reflex, motor function, and sensory control
- Rats (n=6) in the control group receiving saline solution demonstrated no signs of sensory or reflex recovery or motor rehabilitation. ExoPTEN is developed using the company’s ExoTherapy platform
Ref: Globenewswire | Image: NurExone
Related News:- Pfizer and Valneva Report Partial Discontinuation of Patient Evaluation in P-III Clinical Trial for VLA15 to Treat Lyme Disease
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
